Litcius/Paper detail

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet Asım Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales‐Barrera, Michael Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Ann Nelson, Christopher Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgić, Ana Fröbe, Alejo Rodríguez‐Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson‐Velho, Lucía Alonso Buznego, Ignacio Durán, Marcus W. Moses, Albert Jang, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Bruce Montgomery, Petros Grivas, Ali Raza Khaki

2022Clinical Genitourinary Cancer27 citationsDOIOpen Access PDF

Topics & Concepts

MedicineHazard ratioInternal medicineOncologyMetastasisMetastatic Urothelial CarcinomaBone metastasisProportional hazards modelCohortCancerRetrospective cohort studyGastroenterologyBladder cancerUrothelial carcinomaConfidence intervalBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma | Litcius